voriconazol sandoz 200 mg
lek pharmaceuticals d.d. - slovenia - voriconazolum - pulb. pt. sol. perf. - 200 mg - antimicotice de uz sistemic derivati de triazol
voriconazol fresenius kabi 200 mg
fresenius kabi deutschland gmbh - germania - voriconazolum - pulb. pt. sol. perf. - 200mg - antimicotice de uz sistemic derivati de triazol
meropenem accord 1 g
accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 1g - alte antibiotice betalactamice carbapeneme
meropenem accord 500 mg
accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 500mg - alte antibiotice betalactamice carbapeneme
meropenem accord 1 g
accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 1g - alte antibiotice betalactamice carbapeneme
meropenem accord 500 mg
accord healthcare limited - marea britanie - meropenemum - pulb. pt. sol. inj./perf. - 500mg - alte antibiotice betalactamice carbapeneme
caspofungina mylan 70 mg
sag manufacturing s.l.u - spania - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice
pemetrexed mylan 25 mg/ml
synthon hispania, s.l. - spania - pemetrexedum - conc. pt. sol. perf. - 25mg/ml - antimetaboliti analogi ai acidului folic
voriconazol actavis 200 mg
actavis italy s.p.a nerviano plant - italia - voriconazolum - pulb. pt. sol. perf. - 200mg - antimicotice de uz sistemic derivati de triazol
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.